2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crowther, M. A. Articles by Ingram, A. J. Search for Related Content PubMed PubMed Citation Articles by Crowther, M. A. Articles by Ingram, A. J.

Low-Intensity Warfarin Is Ineffective for the Prevention of PTFE Graft Failure in Patients on Hemodialysis: A Randomized Controlled Trial

Mark A. Crowther^*, Catherine M. Clase^*, Peter J. Margetts^*, Jim Julian, Kim Lambert^*, Denise Sneath, Ryuta Nagai, Sarah Wilson^* and Alistair J. Ingram^*

*Department of Medicine and Department of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; and Division of Nephrology, Hotel Dieu Hospital, St. Catharine’s, Ontario, Canada

Correspondence to Dr. Alistair J. Ingram, 708-500 Charlton Ave. East, Hamilton, Ontario. Phone: 905-521-6151; Fax: 905-521-6153; E-mail: ingrama{at}mcmaster.ca

ABSTRACT. Polytetrafluoroethylene (PTFE) dialysis grafts in patients with end-stage renal disease (ESRD) are prone to thrombotic failure. The objective of this multicenter, randomized, double-blind, placebo-controlled clinical trial was to determine if warfarin reduces the risk of failure of PTFE dialysis grafts. Patients with ESRD and newly placed PTFE grafts were studied at community and academic dialysis centers in Southwestern Ontario. Patients were allocated to receive warfarin or matching placebo, with the warfarin administered to achieve a target INR of 1.4 to 1.9. Time to graft failure was the main outcome measure. A total of 107 patients (56 allocated to warfarin) were randomized. The time-to-event analysis revealed no significant difference in the likelihood of graft survival between the two groups (odds ratio, 1.76 in favor of placebo; 95% confidence interval, 0.72 to 4.34). Six major bleeds occurred in five patients allocated to warfarin compared with none in the patients who received placebo (P = 0.03). In conclusion, low-dose warfarin was associated with an excess of clinically important major bleeding in patients with ESRD enrolled in this study. Furthermore, low-intensity, monitored-dose warfarin does not appear to prolong PTFE graft survival.

This article has been cited by other articles:

				S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]

				R. M. Holden, G. J. Harman, M. Wang, D. Holland, and A. G. Day Major Bleeding in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 105 - 110. [Abstract] [Full Text] [PDF]

				S. Khella and M. B. Bleicher Stroke and Its Prevention in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1343 - 1351. [Abstract] [Full Text] [PDF]

				B. H. Lee, J. E. Lee, K. W. Lee, H. Y. Nam, H. J. Jeon, Y. J. Sung, J. S. Kim, H. J. Lim, J.-s. Park, J. Y. Ko, et al. Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2800 - 2804. [Abstract] [Full Text] [PDF]

				P. Sood, G. P. Sinson, and E. P. Cohen Subdural Hematomas in Chronic Dialysis Patients: Significant and Increasing Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 956 - 959. [Abstract] [Full Text] [PDF]

				M. Allon Current Management of Vascular Access Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 786 - 800. [Abstract] [Full Text] [PDF]

				W. M. Bennett Should Dialysis Patients Ever Receive Warfarin and for What Reasons? Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1357 - 1359. [Full Text] [PDF]

				K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton CHAPTER 4: Vascular Access J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S16 - S23. [Full Text] [PDF]

				B. S Dixon, G. J Beck, L. M Dember, T. A Depner, J. J Gassman, T. Greene, J. Himmelfar, L. G Hunsicker, J. S Kaufman, J. H Lawson, et al. Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trial Clinical Trials, October 1, 2005; 2(5): 400 - 412. [Abstract] [PDF]

				M. J. Flanigan Melagatran anticoagulation during haemodialysis--'Primum non nocere' Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1789 - 1790. [Full Text] [PDF]

				G. A. Knoll, P. S. Wells, D. Young, S. L. Perkins, R. M. Pilkey, J. J. Clinch, and M. A. Rodger Thrombophilia and the Risk for Hemodialysis Vascular Access Thrombosis J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1108 - 1114. [Abstract] [Full Text] [PDF]

				T. L. Ortel Thrombosis and the Antiphospholipid Syndrome Hematology, January 1, 2005; 2005(1): 462 - 468. [Abstract] [Full Text] [PDF]

				M. A. Crowther, J. S. Ginsberg, J. Julian, J. Denburg, J. Hirsh, J. Douketis, C. Laskin, P. Fortin, D. Anderson, C. Kearon, et al. A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome N. Engl. J. Med., September 18, 2003; 349(12): 1133 - 1138. [Abstract] [Full Text] [PDF]

				J. S. Kaufman, T. Z. O'Connor, J. H. Zhang, R. E. Cronin, L. D. Fiore, M. B. Ganz, D. S. Goldfarb, and P. N. Peduzzi Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2313 - 2321. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673